Tag: Gilead Sciences

Agenus and Gilead Close I-O Deal

Agenus Inc., an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies, today announced the closing of its immuno-oncology (I-O) partners...

Companies with Most FDA Approvals

In 2018, the U.S. Food and Drug Administration (FDA) approved 59 novel drugs, meaning approved new molecular entities (NMEs). The figure for 2017 was 46 novel drugs. The FDA notes, “Each year, CDER a...

Gilean and Yuhan to Develop NASH Treatment

Gilead Sciences has signed a licensing and collaboration agreement, potentially worth $785m, with South Korea-based Yuhan to develop new therapeutic candidates for the treatment of advanced fibrosis d...

Gilead starts an immuno-oncology partnership with Agenus

gilead sciences
Gilead Sciences and Agenus announced the companies have entered into an immuno-oncology partnership focused on the development and commercialization of up to five novel immuno-oncology therapies.

Gilead Sciences enters into a collaboration with Tango Therapeutics

gilead sciences
Gilead Sciences and Tango Therapeutics, a company focused on the discovery and development of novel cancer therapies, announced a global strategic collaboration.

Gilead and Precision BioSciences to collaborate on novel HBV therapies

gilead sciences
Gilead Sciences and Precision BioSciences announced that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV).

Gilead localizes the production of hepatitis C and HIV drugs in Russia

According to the agreement Pharmstandard production facilities will manufacture Sovaldi® for the treatment of chronic hepatitis C and Truvada® for the treatment of HIV.

Gilead’s HIV treatment obtained EU marketing authorization

Gilead Sciences announced that the European Commission has granted Marketing Authorization for Biktarvy®, a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.

Gilead and Hookipa Biotech will develop HIV and Hepatitis B treatments

gilead sciences
Hookipa Biotech AG, an Austrian clinical-stage biotech company, and Gilead Sciences, a research-based biopharmaceutical company, entered into a research collaboration and license agreement.

Kite obtains new R&D facilities to develop cell therapies

cancer treatment
The new site in Hoofddorp will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.

Gilead Sciences and Verily Life Sciences start a scientific collaboration

Gilead Sciences and Verily Life Sciences announced a scientific collaboration using Verily’s platform to identify and better understand the immunological basis of three common and serious inflammatory diseases.

Gilead and Sangamo joined up for development of next gen cell therapies

Kite, a Gilead Company, and Sangamo Therapeutics entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.

GSK brings legal action against Gilead Sciences

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences

Gilead starts a new clinical collaboration with Pfizer

Kite, a Gilead Company, announced a clinical trial collaboration with Pfizer to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab

Gilead Sciences buys Cell Design Labs

Gilead Sciences and its subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs

Gilead Sciences completed the purchase of Kite Pharma

Gilead Sciences, Inc. announced the completion of the previously announced transaction for a subsidiary of Gilead to acquire Kite Pharma